Harbinger Medical Inc. is a venture backed medical device company that has pioneered Wedensky Modulation technology, with the purpose of developing it into a non-invasive risk stratification system. The Harbinger system goal is to address a key problem in cardiac risk stratification: the identification of patients at elevated risk for Sudden Cardiac Death (SCD). SCD is the largest cause of death among the 20 million adults at elevated cardiac risk worldwide, killing over 850,000 people each year.

An implantable cardioverter defibrillator (ICD) is highly effective at terminating arrhythmias that lead to SCD. However, identification of patients at risk of SCD is difficult, because current tests lack predictive accuracy. Consequently, only a minority of patients currently indicated for ICD implantation actually receives an ICD, and large numbers of patients at risk of SCD are not indicated for ICD therapy. Meanwhile, the majority of patients who receive expensive ICD implants never experience a life-threatening arrhythmia, and are sometimes subjected to unnecessary, excruciatingly painful shocks.

The Harbinger system is a non-invasive, twenty minute test performed on patients at rest. The Harbinger system provides information for at-risk patients by assessing the vulnerability of the heart to potentially lethal arrhythmias.

Two international clinical studies have demonstrated the ability of the Harbinger system to identify patients at risk of SCD. The most recent was the Harbinger ICD Patient ("HIP") Study. Three abstracts on this study were accepted for the US Heart Rhythm Society meeting in May 2008, and four additional abstracts have been accepted at Cardiostim in June 2008.